Distinct Patterns of Endothelin Axis Expression in Primary Prostate Cancer

Urology

Volumn 70, Issue 1, 2007, Pages 209-215

  Godara, Geeta ^a   Pecher, Stefana ^a   Jukic, Drazen M ^a   D'Antonio, Jason M ^a   Akhavan, Ardavan ^a   Nelson, Joel B ^a   Pflug, Beth R ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; MEMBRANE METALLOENDOPEPTIDASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; ENDOTHELIN-1; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B;

EID: 34447513701     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.03.017     Document Type: Article

References (27)

1. Battistini B., D'Orleans-Juste P., and Sirois P. Endothelins: circulating plasma levels and presence in other biologic fluids. Lab Invest 68 (1993) 600-628
2. Langenstroer P., Tang R., Shapiro E., et al. Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies. J Urol 150 (1993) 495-499
3. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415
4. Nelson J.B., Hedican S., George D., et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1 (1995) 944-949
5. Herrmann E., Bogemann M., Bierer S., et al. The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications. Expert Rev Anticancer Ther 6 (2006) 73-81
6. Arai H., Hori S., Aramori I., et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348 (1990) 730-732
7. Sakurai T., Yanagisawa M., and Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol Sci 13 (1992) 103-108
8. Nelson J.B., Lee W.H., Nguyen S.H., et al. Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 57 (1997) 35-37
9. Woodson K., Gillespie J., Hanson J., et al. Heterogeneous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: a histopathologic study of whole mount prostate specimens. Prostate 60 (2004) 25-31
10. Yegnasubramanian S., Kowalski J., Gonzalgo M.L., et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64 (2004) 1975-1986
11. Bagnato A., and Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 14 (2003) 44-50
12. Salani D., Taraboletti G., Rosano L., et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 157 (2000) 1703-1711
13. Davar G. Endothelin-1 and metastatic cancer pain. Pain Med 2 (2001) 24-27
14. De-Melo J.D., Tonussi C.R., D'Orleans-Juste P., et al. Articular nociception induced by endothelin-1, carrageenan and LPS in naive and previously inflamed knee-joints in the rat: inhibition by endothelin receptor antagonists. Pain 77 (1998) 261-269
15. Alam A.S., Gallagher A., Shankar V., et al. Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption. Endocrinology 130 (1992) 3617-3624
16. Nelson J.B., Nguyen S.H., Wu-Wong J.R., et al. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 53 (1999) 1063-1069
17. Freedland S.J., Seligson D.B., Liu A.Y., et al. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate 55 (2003) 71-80
18. Usmani B.A., Shen R., Janeczko M., et al. Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clin Cancer Res 6 (2000) 1664-1670
19. Papandreou C.N., Usmani B., Geng Y., et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 4 (1998) 50-57
20. Shen R., Sumitomo M., Dai J., et al. Identification and characterization of two androgen response regions in the human neutral endopeptidase gene. Mol Cell Endocrinol 170 (2000) 131-142
21. Albrecht M., Mittler A., Wilhelm B., et al. Expression and immunolocalisation of neutral endopeptidase in prostate cancer. Eur Urol 44 (2003) 415-422
22. Gohji K., Kitazawa S., and Tamada H. Expression of endothelin receptor A associated with prostate cancer progression. J Urol 165 (2001) 1033-1036
23. Godara G., Cannon G.W., Cannon Jr. G.M., et al. Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma. Prostate 65 (2005) 27-34
24. Nelson J.B., Udan M.S., Guruli G., et al. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia 7 (2005) 631-637
25. Carducci M.A., Nelson J.B., Bowling M.K., et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 20 (2002) 2171-2180 [erratum appears in J Clin Oncol 21: 2449, 2003]
26. Carducci M.A., Padley R.J., Breul J., et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21 (2003) 679-689
27. Opgenorth T.J., Adler A.L., Calzadilla S.V., et al. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 276 (1996) 473-481